ArticleInternational journal of cancer2009
Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Article in International journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Locus of (IL-9) control: IL9 epigenetic regulation in cellular function and human disease.Experimental & molecular medicine · 2024Review
- Article
- EGFR-HIF1α signaling positively regulates the differentiation of IL-9 producing T helper cells.Nature communications · 2021Article
- Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.Biomolecules · 2020Review
- Identification of lncRNA-mRNA Regulatory Module to Explore the Pathogenesis and Prognosis of Melanoma.Frontiers in cell and developmental biology · 2020Article
- Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.Familial cancer · 2019Article
- Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Article
- Transcriptional Control of Th9 Cells: Role of Foxo1 in Interleukin-9 Induction.Frontiers in immunology · 2018Review
- IL-9 and Th9 cells in health and diseases-From tolerance to immunopathology.Cytokine & growth factor reviews · 2017Review
- TSeminars in immunopathology · 2017Review
- Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.Journal of the American Academy of Dermatology · 2016Review
- Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.BMC research notes · 2015Article
- The development and in vivo function of T helper 9 cells.Nature reviews. Immunology · 2015Review
- Constitutional promoter methylation and risk of familial melanoma.Epigenetics · 2014Article
- Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.Oncotarget · 2014Article
- Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma.PloS one · 2014Article
- Amazing IL-9: revealing a new function for an "old" cytokine.The Journal of clinical investigation · 2012Article
- Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.Nature medicine · 2012Article
- Article
- Evaluation of TRAF6 in a large multiancestral lupus cohort.Arthritis and rheumatism · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
CDKN2A is a major susceptibility gene for cutaneous malignant melanoma (CMM), but the variable penetrance and clinical manifestations among mutation carriers suggest the existence of modifier factors. The goal of this study was to identify modifier genes for CMM in CMM-prone families with or without CDKN2A mutations. We genotyped 537 individuals (107 CMM) from 28 families (19 CDKN2A+, 9 CDKN2A-) for 1,536 SNPs in 152 genes involved in DNA repair, apoptosis and immune response pathways. We used conditional logistic regression to account for family ascertainment and differences in disease prevalence among families. Pathway- and gene-based permutation analyses were used to assess the risk of CMM associated with genes in the 5 pathways (DNA repair, apoptosis, TNF/NFkappaB, TH1:TH2 and other immune regulation). Our analyses identified some candidate genes such as FAS, BCL7A, CASP14, TRAF6, WRN, IL9, IL10RB, TNFSF8, TNFRSF9 and JAK3 that were associated with CMM risk (p<0.01, gene-based test). After correction for multiple comparisons, IL9 remained significant (Bonferroni p<0.05). The effects of some genes were stronger in CDKN2A-positive families (BCL7A and IL9), while some were stronger in CDKN2A-negative families (BCL2L1). Our findings support the hypothesis that common genetic polymorphisms in DNA repair, apoptosis and immune response pathways may modify the risk of CMM in CMM-prone families with or without CDKN2A mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.